Rudy Li
Stock Analyst at Wolfe Research
(5.00)
# 18
Out of 5,182 analysts
40
Total ratings
81.08%
Success rate
112.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Rudy Li
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CNTA Centessa Pharmaceuticals | Downgrades: Peer Perform | n/a | $39.66 | - | 6 | Mar 31, 2026 | |
| ALKS Alkermes | Initiates: Outperform | $45 | $34.53 | +30.32% | 1 | Feb 24, 2026 | |
| AXSM Axsome Therapeutics | Initiates: Outperform | $230 | $188.99 | +21.70% | 1 | Feb 24, 2026 | |
| XENE Xenon Pharmaceuticals | Initiates: Outperform | $60 | $59.70 | +0.50% | 5 | Feb 24, 2026 | |
| STOK Stoke Therapeutics | Initiates: Outperform | $40 | $37.27 | +7.32% | 5 | Feb 24, 2026 | |
| QURE uniQure | Initiates: Peer Perform | n/a | $17.58 | - | 1 | Feb 24, 2026 | |
| DNLI Denali Therapeutics | Initiates: Peer Perform | n/a | $20.57 | - | 1 | Feb 24, 2026 | |
| PRAX Praxis Precision Medicines | Initiates: Outperform | $500 | $342.50 | +45.99% | 4 | Feb 24, 2026 | |
| NBIX Neurocrine Biosciences | Initiates: Outperform | $160 | $133.25 | +20.08% | 1 | Feb 24, 2026 | |
| DFTX Definium Therapeutics | Initiates: Outperform | $25 | $22.68 | +10.23% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $22.17 | +48.85% | 1 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 | $89.90 | -11.01% | 3 | Jan 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $1.00 | +200.00% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $27.72 | -45.89% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $0.85 | +4,605.88% | 1 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 | $10.90 | +65.14% | 7 | Aug 28, 2025 |
Centessa Pharmaceuticals
Mar 31, 2026
Downgrades: Peer Perform
Price Target: n/a
Current: $39.66
Upside: -
Alkermes
Feb 24, 2026
Initiates: Outperform
Price Target: $45
Current: $34.53
Upside: +30.32%
Axsome Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $230
Current: $188.99
Upside: +21.70%
Xenon Pharmaceuticals
Feb 24, 2026
Initiates: Outperform
Price Target: $60
Current: $59.70
Upside: +0.50%
Stoke Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $40
Current: $37.27
Upside: +7.32%
uniQure
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $17.58
Upside: -
Denali Therapeutics
Feb 24, 2026
Initiates: Peer Perform
Price Target: n/a
Current: $20.57
Upside: -
Praxis Precision Medicines
Feb 24, 2026
Initiates: Outperform
Price Target: $500
Current: $342.50
Upside: +45.99%
Neurocrine Biosciences
Feb 24, 2026
Initiates: Outperform
Price Target: $160
Current: $133.25
Upside: +20.08%
Definium Therapeutics
Feb 24, 2026
Initiates: Outperform
Price Target: $25
Current: $22.68
Upside: +10.23%
Feb 24, 2026
Initiates: Outperform
Price Target: $33
Current: $22.17
Upside: +48.85%
Jan 2, 2026
Maintains: Buy
Price Target: $80
Current: $89.90
Upside: -11.01%
Sep 29, 2025
Initiates: Buy
Price Target: $3
Current: $1.00
Upside: +200.00%
Sep 29, 2025
Initiates: Buy
Price Target: $15
Current: $27.72
Upside: -45.89%
Sep 29, 2025
Initiates: Buy
Price Target: $40
Current: $0.85
Upside: +4,605.88%
Aug 28, 2025
Maintains: Buy
Price Target: $18
Current: $10.90
Upside: +65.14%